After Canceling IPO, Radius May Tap Institutional Investors

With its IPO withdrawn, osteoporosis drug developer Radius Therapeutics is likely to seek funding from institutional backers. The company has just enough cash to last it through the first quarter, with big costs for a Phase III trial in the works.